Fennec Pharmaceuticals Inc. FENC
11.57 USD +0.67 (+6.15%)
Nov 13, 2026, 10:13 AM EST
10.97 Day range 11.53
5.65 52-week range 13.25
- YTD
- +50.26%
- 1 year
- +50.46%
News
seekingalpha.com Fennec Pharmaceuticals Inc. (FENC) Q3 2026 Earnings Call Transcript Fennec Pharmaceuticals Inc. (FENC) Q3 2026 Earnings Call Transcript
marketbeat.com Adherex Technologies Q3 Earnings Call Highlights Fennec Pharmaceuticals NASDAQ: FENC reported third-quarter net product sales of $19.4 million, up 56% from a year earlier, as use of its hearing-protection drug PEDMARK expanded among new and…
benzinga.com Fennec Pharmaceuticals Q3 2026 Earnings Call Transcript Fennec Pharmaceuticals (NASDAQ:FENC) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
zacks.com Adherex Technologies Inc. (FENC) Q3 Earnings and Revenues Beat Estimates Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to a loss of $0.02 per share a year ago.
benzinga.com Fennec Pharmaceuticals Q3 EPS $0.12 Beats $0.10 Estimate, Sales $19.608M Beat $18.401M Estimate Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.10 by 20 percent. This is a 700 percent increase over losses of…
globenewswire.com Fennec Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update ~ Third Quarter 2026 Net Product Sales of $19.4 Million, Up 56% Year over Year ~ ~ Third Quarter 2026 Non-GAAP Adjusted EBITDA of $5.8 Million ~ ~ With $6.7 Million in Positive Cash Flow from…
globenewswire.com Fennec Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 12, 2026 RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the…
benzinga.com HC Wainwright & Co. Reiterates Buy on Fennec Pharmaceuticals, Maintains $16 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains $16 price target.
benzinga.com B. Riley Securities Reiterates Buy on Fennec Pharmaceuticals, Raises Price Target to $18 B. Riley Securities analyst Madison El-Saadi reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $16 to $18.
benzinga.com Wedbush Maintains Outperform on Fennec Pharmaceuticals, Raises Price Target to $16 Wedbush analyst David Nierengarten maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Outperform and raises the price target from $13 to $16.
benzinga.com Fennec Pharmaceuticals Q2 EPS $0.05 Beats $0.02 Estimate, Sales $17.874M Beat $16.095M Estimate Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.02 by 150 percent. This is a 145.45 percent increase over losses of…- benzinga.com HC Wainwright & Co. Maintains Buy on Fennec Pharmaceuticals, Raises Price Target to $16 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $13 to $16.
benzinga.com Fennec Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript 
benzinga.com Earnings Scheduled For May 14, 2026 
benzinga.com Wedbush Reiterates Outperform on Fennec Pharmaceuticals, Maintains $13 Price Target Wedbush analyst David Nierengarten reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Outperform and maintains $13 price target.- benzinga.com Fennec Pharma Initiates Investigator-Sponsored Study By University Of Arizona Cancer Center To Evaluate Use Of PEDMARK In Adolescent And Young Adult And Adult Patients With Head And Neck And Testicular Cancers Receiving Cisplatin ~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~~ This New Study and Other Independent,…
benzinga.com Fennec Pharmaceuticals Q4 GAAP EPS $(0.17) Misses $0.04 Estimate, Sales $13.777M Miss $13.993M Estimate Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $0.04 by 572.22 percent. This is a 183.33 percent decrease over…- benzinga.com Earnings Scheduled For March 24, 2026
benzinga.com Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call Fennec Pharmaceuticals (FENC) to release Q4 earnings on March 24. Analysts expect EPS of $0.04 and revenue of $14.73 million. Stock gained 1.8% on Monday.- benzinga.com Fennec Pharmaceuticals Settles PEDMARK Patent Litigation With Cipla; Blocking Generic Entry Until September 2033 Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announces that it has entered into an agreement with Cipla Limited and Cipla USA, Inc. to settle the…
- benzinga.com Fennec Pharma Backs Real-World Study Of PEDMARK To Protect Hearing In Cancer Patients Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announced that the Tampa General Hospital (TGH) Cancer Institute is initiating a study evaluating the…
- benzinga.com Piper Sandler Initiates Coverage On Fennec Pharmaceuticals with Overweight Rating, Announces Price Target of $18 Piper Sandler analyst David Amsellem initiates coverage on Fennec Pharmaceuticals (NASDAQ:FENC) with a Overweight rating and announces Price Target of $18.
benzinga.com Pedmark Delivers In Japan Study — Less Hearing Loss, Same Cancer-Fighting Power Pedmark cut cisplatin-related hearing loss in a Japan trial, with strong safety and no impact on tumor response, supporting plans for Japan registration.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Fennec Pharmaceuticals Released Topline Results From Phase 2/3 STS-J01 Trial Of Pedmark (Sodium Thiosulfate Injection) For The Reduction Of Cisplatin-induced Ototoxicity In Pediatric And Adolescent And Young Adult Patients With Non-metastatic Solid Tumors In Japan Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK when Compared with Historically Reported Rates of…
benzinga.com Reported Earlier, Fennec Pharmaceuticals Prices Offering Of 4,666,667 Common Shares At $7.50 Per Share For ~$35M In Gross Proceeds Fennec intends to use the net proceeds of the offering to repurchase and redeem certain indebtedness and the remaining net proceeds, if any, for working capital and general corporate purposes.- benzinga.com Fennec Pharmaceuticals Q3 EPS $(0.02), Inline, Sales $12.462M Beat $11.257M Estimate Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. This is a 90.48 percent increase over losses of $(0.21) per share from…
- benzinga.com Fennec Pharmaceuticals Plans To Launch Common Stock Offering; Terms Not Disclosed Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) ("Fennec" or the "Company"), a specialty pharmaceutical company, today announced that it intends to offer and sell its common shares in an…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Fennec Pharmaceuticals, Maintains $13 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains $13 price target.
- benzinga.com Craig-Hallum Maintains Buy on Fennec Pharmaceuticals, Raises Price Target to $14 Craig-Hallum analyst Chase Knickerbocker maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $13 to $14.
- benzinga.com Fennec Pharmaceuticals Q2 EPS $(0.11) Misses $(0.04) Estimate, Sales $9.65M Beat $9.52M Estimate Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.04) by 205.56 percent. This is a 45 percent increase over losses…
- benzinga.com Earnings Scheduled For August 14, 2025
- benzinga.com Fennec Pharmaceuticals Earnings Preview
- benzinga.com HC Wainwright & Co. Reiterates Buy on Fennec Pharmaceuticals, Maintains $13 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains $13 price target.
- benzinga.com Craig-Hallum Maintains Buy on Fennec Pharmaceuticals, Raises Price Target to $13 Craig-Hallum analyst Chase Knickerbocker maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $12 to $13.
- benzinga.com Fennec Pharmaceuticals Q1 EPS $(0.04) Beats $(0.09) Estimate, Sales $8.75M Beat $8.18M Estimate Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.09) by 55.56 percent. This is a 109.76 percent decrease over…
- benzinga.com Earnings Scheduled For May 13, 2025
- benzinga.com HC Wainwright & Co. Reiterates Buy on Fennec Pharmaceuticals, Maintains $13 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains $13 price target.
benzinga.com Nasdaq, S&P 500 Hit 6-Month Lows As Recession Fears Grow: What's Driving Markets Monday? Stocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq 100 saw the steepest declines, with Tesla, Inc. (NASDAQ:TSLA) and Palantir…
benzinga.com Earnings Scheduled For March 10, 2025 
benzinga.com Why BP Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket - benzinga.com Why Alibaba Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- benzinga.com Earnings Scheduled For March 21, 2024 Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million.
- benzinga.com Earnings Scheduled For November 6, 2023 Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 311 stocks hit new 52-week lows.
- benzinga.com Earnings Scheduled For August 3, 2023 Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
- benzinga.com Earnings Scheduled For May 11, 2023 Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its…
- benzinga.com Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday Gainers
- benzinga.com Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Wednesday's Mid-Day Session Gainers
- benzinga.com Stocks That Hit 52-Week Highs On Monday During Monday's morning session, 179 stocks hit new 52-week highs.